Skip to main content

Table 2 Univariate and multivariate analyses of prognostic factors for PFS and OS

From: Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications

   PFS OS
Univariate Multivariate Univariate Multivariate
Variables   HR (95%CI) P HR (95%CI) P HR (95%CI) P HR (95%CI) P
Age, years ≥50 0.49 (0.30–0.80) 0.004 0.45 (0.27–0.76) 0.002 0.55 (0.31–0.97) 0.040 0.58 (0.33–1.04) 0.065
Sex Female 1.57 (0.85–2.89) 0.152    0.94 (0.44–2.00) 0.863   
HBsAg Positive 1.02 (0.51–2.08) 0.947    1.10 (0.47–2.60) 0.823   
Child Pugh class B 1.19 (0.59–2.40) 0.636    1.83 (0.89–3.79) 0.103   
BCLC stage C 0.76 (0.40–1.44) 0.397    1.40 (0.63–3.12) 0.413   
Extrahepatic metastasis Yes 1.23 (0.75–2.01) 0.418    1.32 (0.74–2.33) 0.346   
AFP level ≥ 400μg/ml Yes 1.02 (0.62–1.67) 0.941    1.01 (0.57–1.78) 0.981   
Prior systemic treatment Yes 2.00 (0.98–4.06) 0.057    1.49 (0.70–3.19) 0.304   
Prior TACE Yes 1.17 (0.71–1.93) 0.547    0.69 (0.38–1.25) 0.221   
Maximum diameter of ≥5 cm Yes 1.45 (0.78–2.69) 0.236    1.86 (0.87–3.98) 0.110   
Tumor occupation ≥50% Yes 2.50 (1.49–4.18) < 0.001 2.66 (1.57–4.49) < 0.001 3.98 (2.19–7.22) < 0.001 3.90 (2.14–7.12) < 0.001
Invasion with Vp4 Yes 0.85 (0.50–1.43) 0.528    0.95 (0.52–1.72) 0.855